Home » Stocks » IQV

IQVIA Holdings Inc. (IQV)

Stock Price: $172.00 USD 1.44 (0.84%)
Updated November 24, 4:03 PM EST - Market closed
After-hours: $170.96 -1.04 (-0.61%) Nov 24, 7:59 PM

Stock Price Chart

Key Info

Market Cap 32.98B
Revenue (ttm) 10.96B
Net Income (ttm) 176.00M
Shares Out 191.73M
EPS (ttm) 0.91
PE Ratio 189.01
Forward PE 21.69
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $172.00
Previous Close $170.56
Change ($) 1.44
Change (%) 0.84%
Day's Open 172.87
Day's Range 170.78 - 173.82
Day's Volume 742,773
52-Week Range 81.79 - 180.77

More Stats

Market Cap 32.98B
Enterprise Value 44.16B
Earnings Date (est) Feb 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 191.73M
Float 189.72M
EPS (basic) 0.93
EPS (diluted) 0.91
FCF / Share 6.35
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.53%
FCF Yield 3.68%
Payout Ratio n/a
Shares Short 1.90M
Short Ratio 1.96
Short % of Float 1.00%
Beta 1.45
PE Ratio 189.01
Forward PE 21.69
P/FCF Ratio 27.14
PS Ratio 3.01
PB Ratio 5.59
Revenue 10.96B
Operating Income 608.00M
Net Income 176.00M
Free Cash Flow 1.22B
Net Cash -11.18B
Net Cash / Share -58.33
Gross Margin 34.57%
Operating Margin 5.55%
Profit Margin 1.60%
FCF Margin 11.09%
ROA 1.90%
ROE 3.17%
ROIC 5.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (23)

Buy 18
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$200.00*
(16.28% upside)
Low
175
Current: $172.00
High
227
Target: 200.00
*Average 12-month price target from 19 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11,08810,4129,7026,8155,7375,4605,1004,8664,3283,924
Revenue Growth6.49%7.32%42.36%18.79%5.07%7.07%4.81%12.43%10.29%-
Gross Profit3,7883,6663,4012,0671,6211,5011,3371,2331,1421,119
Operating Income777741665576646590462396345395
Net Income1912591,27772.00387357227178242161
Shares Outstanding195204218149123128124116116116
Earnings Per Share0.961.245.740.473.082.721.771.512.051.36
EPS Growth-22.58%-78.4%1121.28%-84.74%13.24%53.67%17.22%-26.34%50.74%-
Operating Cash Flow1,4171,254970860476433393336161378
Capital Expenditures-582-459-369-164-78.00-83.00-86.33-68.61-72.70-77.68
Free Cash Flow83579560169639835030726788.25300
Cash & Equivalents8999381,0051,238977870781571519-
Total Debt12,04111,00710,2257,2002,4682,2832,0462,4221,972-
Net Cash / Debt-11,142-10,069-9,220-5,962-1,491-1,413-1,265-1,851-1,453-
Assets23,25122,54922,85721,2083,9263,2963,0672,4992,323-
Liabilities16,98815,59514,61312,3484,2624,0003,7343,8583,293-
Book Value6,0036,7147,9958,633-564-704-667-1,360-970-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IQVIA Holdings Inc.
Country United States
Employees 68,000
CEO Ari Bousbib

Stock Information

Ticker Symbol IQV
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NYSE: IQV
IPO Date May 9, 2013

Description

IQVIA Holdings provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.